Última actualización 4 de julio de 2026
Key finding
HbA1c level decreased by 1.19% (95% CI, -1.54% to -0.84%) with the 15 mg dose.
This study evaluated the efficacy and safety of HRS-7535 in adults with type 2 diabetes inadequately controlled with metformin, showing significant reductions in HbA1c and fasting plasma glucose levels.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Guarda este estudio en tu Evidence Tracker para encontrarlo facilmente cuando lo necesites.
Plain-language summary
A plain-language read of the study's main message and where it applies.
Study focus
This study evaluated the efficacy and safety of HRS-7535 in adults with type 2 diabetes inadequately controlled with metformin, showing significant reductions in HbA1c and fasting plasma glucose levels.
These findings are significant as they suggest that HRS-7535 could be an effective treatment option for adults with type 2 diabetes who are not achieving adequate glycemic control with metformin alone. Improved blood sugar management can lead to better overall health outcomes and reduce the risk of diabetes-related complications.
The study's population may not represent all adults with type 2 diabetes. Long-term safety and efficacy data are lacking. The sample size for each treatment group may limit generalizability.
Published in
Publication details and source links for this paper.
Lixin G, Zilin S, Lihui Z, et al. Efficacy and Safety of HRS-7535 in Adults with Type 2 Diabetes Inadequately Controlled with Metformin. JAMA Network Open. 2026;9(6):e2615622. doi:10.1001/jamanetworkopen.2026.15622
HRS-7535 (15 mg) reduced HbA1c by 1.19% (p=0.001).
HRS-7535 (30 mg) reduced HbA1c by 1.59% (p=0.001).
HRS-7535 (60 mg) reduced HbA1c by 1.82% (p=0.001).
HRS-7535 (90 mg) reduced HbA1c by 1.64% (p=0.001).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to HRS-7535 (15 mg), HRS-7535 (30 mg), HRS-7535 (60 mg), and 1 more and Fasting Plasma Glucose (FPG), HbA1c.
This study contributes evidence to
Primary intervention
HRS-7535 (15 mg)
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
8
Evidence pairs
319
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
matched_outcome
Evidencia relacionada
Tema de evidencia
Seguir evidencia
Core evidence
The primary outcomes reported in this study.
HRS-7535 (15 mg) → Fasting Plasma Glucose (FPG)
HRS-7535 (15 mg) → Fasting Plasma Glucose (FPG)
HRS-7535 (30 mg) → Fasting Plasma Glucose (FPG)
HRS-7535 (30 mg) → Fasting Plasma Glucose (FPG)
HRS-7535 (60 mg) → Fasting Plasma Glucose (FPG)
HRS-7535 (60 mg) → Fasting Plasma Glucose (FPG)
HRS-7535 (90 mg) → Fasting Plasma Glucose (FPG)
HRS-7535 (90 mg) → Fasting Plasma Glucose (FPG)
Create a free account to save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Today's Activity
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.
Today's Activity
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on HRS-7535 (15 mg) and Fasting Glucose, HRS-7535 (15 mg) and HbA1c.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Fasting Glucose
Measures Fasting Glucose as a key outcome.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies on HRS-7535 (15 mg)
Contributes to HRS-7535 (15 mg) evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in the evidence archive.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
HRS-7535 (15 mg) appears to improve Fasting Plasma Glucose (FPG).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
HRS-7535 (15 mg) appears to improve HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
HRS-7535 (30 mg) appears to improve Fasting Plasma Glucose (FPG).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
HRS-7535 (30 mg) appears to improve HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, archive views, and research summaries.
Follow the topics this study contributes to.
Open broader archive views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.